Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/29249
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Moustafa, Farès | en_US |
dc.contributor.author | Pesavento, Raffaele | en_US |
dc.contributor.author | di Micco, Pierpaolo | en_US |
dc.contributor.author | González-Martínez, José | en_US |
dc.contributor.author | Quintavalla, Roberto | en_US |
dc.contributor.author | Peris, Maria-Luisa | en_US |
dc.contributor.author | Porras, José Antonio | en_US |
dc.contributor.author | Falvo, Nicolas | en_US |
dc.contributor.author | Baños, Pilar | en_US |
dc.contributor.author | Monreal, Manuel | en_US |
dc.contributor.author | Bosevski M | en_US |
dc.contributor.author | Zdraveska M | en_US |
dc.date.accessioned | 2024-02-09T10:45:30Z | - |
dc.date.available | 2024-02-09T10:45:30Z | - |
dc.date.issued | 2018-04 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.12188/29249 | - |
dc.description.abstract | We assessed the real-life use of direct oral anticoagulants (DOACs) in patients with venous thromboembolism (VTE) and exclusion criteria for randomized trials. From 2013 to 2016, 3,578 of 18,853 patients (19%) had exclusion criteria. Irrespective of which anticoagulant was chosen, they had more VTE recurrences (hazard ratio (HR): 3.10; 95% confidence interval (CI): 2.47-3.88), major bleeds (HR: 4.10; 95% CI: 3.38-4.96), and deaths (HR: 9.47; 95% CI: 8.46-10.6) than those without exclusion criteria. During initial therapy, no patient with exclusion criteria on DOACs (n = 115) recurred, but those on rivaroxaban bled less often (adjusted HR: 0.18; 95% CI: 0.04-0.79) than those on unfractionated heparin (n = 224) and similar to those (n = 3,172) on low-molecular-weight (LMWH) heparin. For long-term therapy, patients on rivaroxaban (n = 151) had nonsignificantly fewer VTE recurrences (adjusted HR: 0.74; 95% CI: 0.08-1.32) and major bleeds (adjusted HR: 0.41; 95% CI: 0.15-1.15) than those on LMWH (n = 2,071). The efficacy and safety of DOACs were similar to standard therapy. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.ispartof | Clinical Pharmacology & Therapeutics | en_US |
dc.title | Real-life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1002/cpt.781 | - |
dc.identifier.url | https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcpt.781 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.781 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/full-xml/10.1002/cpt.781 | - |
dc.identifier.url | https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.781 | - |
dc.identifier.volume | 103 | - |
dc.identifier.issue | 4 | - |
dc.identifier.fpage | 684 | - |
dc.identifier.lpage | 691 | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
crisitem.author.dept | Faculty of Medicine | - |
crisitem.author.dept | Faculty of Medicine | - |
Appears in Collections: | Faculty of Medicine: Journal Articles |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.